In vivoimaging models of bone and brain metastases and pleural carcinomatosis with a novel humanEML4-ALKlung cancer cell line

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

(2014) Tatsushi Kodama et al.   CANCER LETTERS

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

(2013) Justin F. Gainor et al.   Journal of Thoracic Oncology

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

(2013) Tianhong Li et al.   Journal of Thoracic Oncology

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

(2012) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer

(2012) M. Soda et al.   CLINICAL CANCER RESEARCH

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

(2012) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Treating ALK-positive lung cancer—early successes and future challenges

(2012) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

ALKoma: A Cancer Subtype with a Shared Target

(2012) Hiroyuki Mano   Cancer Discovery

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NKX2.2 Suppresses Self-Renewal of Glioma-Initiating Cells

(2010) T. Muraguchi et al.   CANCER RESEARCH

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA